步长制药: 山东步长制药股份有限公司关于控股子公司获得药品注册证书的公告

Group 1 - The company’s subsidiary, Jilin Tiancheng Pharmaceutical Co., Ltd., has received the drug registration certificate for Benzylsuccinate Atracurium Injection from the National Medical Products Administration [1] - Benzylsuccinate Atracurium Injection is classified as a chemical drug (Category 4) and is a prescription drug [1] - The drug is indicated for use in surgeries, other procedures, and intensive care treatment, serving as an adjunct to general anesthesia and providing muscle relaxation for intubation and mechanical ventilation [1] Group 2 - The annual sales of Benzylsuccinate Atracurium Injection are projected to increase from 609.96 million yuan in 2022 to 818.53 million yuan in 2024 [2] - The company has invested approximately 11.15 million yuan in research and development for the Benzylsuccinate Atracurium Injection project [2] - The drug registration certificate is valid until May 19, 2030, and the production enterprise must comply with Good Manufacturing Practice (GMP) requirements [1][3]